KELIX acquires a Moroccan manufacturer; Catalent’s corporate responsibility report sustainability and charitable focus – Endpoints News


A Dubai biopharmaceutical manufacturer has acquired PHI, one of Morocco’s leading pharmaceutical manufacturers, as part of a larger plan to provide healthcare coverage to residents of the country. KELIX biological will use the purchase to accelerate the rollout of this plan, which it calls Assurance Maladie Obligatoire, or AMO for short. Morocco represents a market of 2 billion dollars in annual pharmaceutical consumption.

“We think we have found at KELIX biological and its leadership the perfect home for our business and we are excited about what the future holds for our employees, our partners and our business,” CEO Ali Sedrati said in a statement. “We have full confidence in KELIX biological expand the company’s reach and continue to pursue its mission of providing quality pharmaceutical products to as many people as possible.

PHI was established in 1989 by the Sedrati family and is a leader in manufacturing and distribution.

Sustainability and Charitable Orientation of Catalent’s Corporate Responsibility Report

Catalent’s third corporate responsibility report revealed the company has donated more than $1 million to philanthropic efforts, including local Covid-19 relief efforts and advancing programs STEM in education.

The company has also reduced its carbon emissions by 15%, gradually moving closer to its goal of reducing Scope 1 and 2 emissions by 42% by 2030.

“No one could have predicted the events of the past two years globally, but in what has been another extraordinary and challenging year, we have made great strides in many areas,” the CEO said. John Chiminski in a press release. .

The CDMO also noted that as of July 1, a “significant majority” of sites are supplied with 100% renewable energy.


Comments are closed.